How long does Ensifentrine usually take?

Ohtuvayre (Ensifentrine) - Ensefentine/Ensefentrine Inhalation Suspension is an innovative inhaled drug that is gradually being accepted globally for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Its biggest feature is that it combines the dual inhibitory functions of PDE3 and PDE4 to achieve a dual-effect mechanism of bronchodilation and anti-inflammation, so it shows unique advantages in maintenance treatment. The duration of medication needs to be understood from the chronic disease maintenance treatment attributes it is positioned for. Exefentine is not an emergency drug for short-term relief of symptoms, but a maintenance treatment program for daily inhalation at regular intervals. Its main purpose is to improve airway function in the long term, delay the deterioration of the condition, and reduce the frequency of acute exacerbations.

In general, patients need to use exefantine continuously and regularly by inhalation, and the treatment period may last from weeks to years. The specific duration needs to be adjusted based on the patient's disease severity, lung function assessment, previous treatment history, and changes in overall quality of life. In most cases, doctors will recommend continued use for at least 8 to 12 weeks as an evaluation period to determine whether the drug is effective on an individual basis. After the evaluation period, if there is significant improvement in clinical symptoms, lung function, activity tolerance and other indicators, it is usually recommended to continue long-term use. If some patients are combined with other bronchodilators (such as LAMA or LABA drugs), exefentine can be used as a complementary therapy in conjunction with them, and its efficacy will reflect the long-term value of the multi-drug combination.

It should be particularly emphasized that since COPD is an irreversible and progressive lung disease, the goal of treatment is not to “completely cure” it, but to control the course of the disease and improve the quality of life through long-term medication. Therefore, the use of exefantine is usually included as part of long-term disease management. Patients should avoid stopping medication without permission after symptoms are relieved, because stopping inhaled therapy may lead to rapid decline in lung function or an increased risk of exacerbation.

Reference materials: https://www.drugs.com/monograph/ensifentrine.html